MedClean Technologies, Inc.(fka MCLN)

[Jukimol]

Goldman Small Cap Research Covers MedClean (OTC:MCLN)
Staff and Wire Reports
Wednesday, 09 December 2009 04:52

Senior research analyst rates MedClean a "Speculative Buy" and believes share price could reach $0.40 early next year as the company executes its plan.

Rob Goldman, a former Piper Jaffray's analyst with over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager has initiated coverage on MedClean (OTC:MCLN). In his report (available for free download to members of BioMedReports) he gives the firm a near-term target of $0.14 and an early 2010 price target of $0.40.

During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology research team covering Israeli Technology and Communications Software. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group as well as the Firm's Israeli research team. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

link:
http://biomedreports.com/articles/subscriber-only-content/21414-goldman-small-cap-research-covers-medclean-otcmcln.html